Our lead asset has pipeline-in-a-product potential and
our IP enables expansion into multiple therapeutic areas
Program | Therapeutic Area | Development Phase | Status | ||||
Discovery | IND-Enabling | 1 | 2 | 3 | |||
CB-502* | MRSA / MSSA (S. aureus) | Phase | Clinical Trial Expected 2Q26 | |||||
CB-212 | Recurrent UTIs (E. coli) | ||||||
CB-105 | Cystic Fibrosis (P. aeruginosa) | ||||||
CB-321 | Surgical Infection (S. epidermidis) | ||||||
CB-424 | Acne (C. acnes) | ||||||
Broad IP Platform covering multiple genetically-modified bacteria | |||||||
* = Including recurrent skin and soft tissue infection (rSSTI), surgical site infection (SSI), cystic fibrosis, dialysis